Wikipedia

José-Alain Sahel

José-Alain Sahel is a French ophthalmologist and scientist. He is currently the chair of the Department of Ophthalmology at the University of Pittsburgh School of Medicine, director of the UPMC Vision Institute, and the Eye and Ear Foundation Chair of Ophthalmology. Dr. Sahel previously led the Vision Institute (French: Institut de la Vision) in Paris, a research center associated with one of the oldest eye hospitals of Europe - Quinze-Vingts National Eye Hospital in Paris, founded in 1260. He is a pioneer in the field of artificial retina and eye regenerative therapies.[1] He is a member of the French Academy of Sciences.

José-Alain Sahel
Born
Algeria
NationalityFrench
Alma materUniversity of Strasburg
AwardsThe Legion of Honour (2008); National Order of Merit (2002); Wolf Prize in Medicine (2024)
Scientific career
FieldsOphthalmology
InstitutionsThe Vision Institute, Paris

Biography

edit

José-Alain Sahel held the chair of the Professor of Ophthalmology at the University Pierre and Marie Curie in Paris and the Professor of Biomedical Sciences (Cumberlege Chair) at University College London.[2] He performed a research fellowship at Massachusetts Eye and Ear Infirmary, Harvard Medical School with Professor Daniel. M. Albert and a visiting scholarship at Harvard Biological Laboratories with Professor John. E. Dowling.[citation needed][3]

In October 2016, José-Alain Sahel was hired by the University of Pittsburgh School of Medicine as chair of the Department of Ophthalmology, the director of the UPMC Vision Institute, and the Eye and Ear Foundation Chair of Ophthalmology.[4] The UPMC Vision Institute headquarters is housed in the Mercy Pavilion and opened in May 2023.[5] In this facility, clinicians and researchers are brought together under one roof, enabling collaboration and integregration of research into patient care. In addition to being the chairperson of the University of Pittsburgh Ophthalmology Department, José-Alain practices as a physician specializing in retina and vitreous disease, with a focus on inherited retinal degenerations and age-related macular degeneration.

Research

edit

José-Alain Sahel is a clinician-scientist conducting research on vision restoration focusing on cellular and molecular mechanisms underlying retinal degeneration, and development of treatments for currently untreatable retinal diseases.[6] He has continued to work to understand and prevent vision loss from photoreceptor cell degeneration and developing vision restoration strategies. His clinical research works closely with experimental research such as information processing, genetic therapeutic research including modeling, evidence of pre-clinical concepts, technological developments in imaging and surgery. His research has conducted to clinical trials on retinal conditions, gene therapy, retinal prothesis, and optogenetics.[7]

Together with his team, José-Alain Sahel worked on the conception, development, and evaluation of treatments for retinal diseases, with a focus on genetic rod-cone dystrophies,[8] including neuroprotection, stem cells, gene therapy, pharmacology, and artificial retina.

His research contributed to demonstrate that rod photoreceptors produce a protein that rescues cone photoreceptors, thereby maintaining light-adapted and high-resolution vision. His research team along with S. Mohand-Said and Thierry Léveillard, identified the underlying signal: Rod-derieved Cone Viability Factor or RdCVF[9] and determined its mechanisms of action as associated with the stimulation of aerobic glycolysis and antioxidant.[10]

Selected publications

edit

References

edit
  1. ^ José-Alain Sahel, master of vision (Report). CNRS. 2012. p. 23. Retrieved 2018-04-11.
  2. ^ "University College London profile for José-Alain Sahel". iris.ucl.ac.uk. University College London. Archived from the original on 2016-03-04. Retrieved 2018-02-08.
  3. ^ Vitone, Elaine (2016). ""Into a World of Light"". Pitt Med Magazine. Cited work between Sahel and Dowling.
  4. ^ "Quest to Cure Blindness: Pitt, UPMC Recruit World-Renowned Expert in Research and Therapies for Blindness and Vision Impairment". University of Pittsburgh Medical Center. 2016-10-05. Retrieved 2018-04-11.
  5. ^ "UPMC Vision Institute Opens Urgent Eye Care Clinic". UPMC | Life Changing Medicine. Retrieved 2024-12-06.
  6. ^ "José-Alain Sahel, MD". Regenerative Medicine at the McGowan Institute. Retrieved 2024-12-06.
  7. ^ "José-Alain Sahel, MD". UPMC Enterprises. Retrieved 2024-12-06.
  8. ^ Authié, Colas Nils; Poujade, Mylène; Talebi, Alireza; Defer, Alexis; Zenouda, Ariel; Coen, Cécilia; Mohand-Said, Saddek; Chaumet-Riffaud, Philippe; Audo, Isabelle; Sahel, José-Alain (February 2024). "Development and Validation of a Novel Mobility Test for Rod-Cone Dystrophies: From Reality to Virtual Reality". American Journal of Ophthalmology. 258: 43–54. doi:10.1016/j.ajo.2023.06.028. ISSN 1879-1891. PMID 37437832.
  9. ^ Aït-Ali, Najate; Fridlich, Ram; Millet-Puel, Géraldine; Clérin, Emmanuelle; Delalande, François; Jaillard, Céline; Blond, Frédéric; Perrocheau, Ludivine; Reichman, Sacha; Byrne, Leah C.; Olivier-Bandini, Anne; Bellalou, Jacques; Moyse, Emmanuel; Bouillaud, Frédéric; Nicol, Xavier (2015-05-07). "Rod-derived cone viability factor promotes cone survival by stimulating aerobic glycolysis". Cell. 161 (4): 817–832. doi:10.1016/j.cell.2015.03.023. ISSN 1097-4172. PMID 25957687.
  10. ^ Object, object (2015). "Rod-Derived Cone Viability Factor Promotes Cone Survival by Stimulating Aerobic Glycolysis". Cell. 7 (161).
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=José-Alain_Sahel&oldid=1262716702"